CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Buck Institute for Age Research |
Dr. Xianmin Zeng |
Research Training II |
CIRM Research Training Program in Stem Cells and Aging |
$1,472,416 |
| University of California, Davis |
Dr. Frederick J Meyers MD |
Research Training II |
UC Davis Stem Cell Training Program |
$4,838,291 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg |
Research Training II |
Training Program in Stem Cell Biology and Engineering |
$2,448,823 |
| University of California, San Francisco |
Dr. Susan J Fisher PhD |
Research Training II |
Training Program in Stem Cell Research at UCSF |
$7,814,027 |
| University of California, Berkeley |
Ellen Robey |
Research Training II |
Interdisciplinary Training in Stem Cell Biology, Engineering and Medicine |
$6,888,557 |
| University of Southern California |
Dr. Robert E Maxson |
Research Training II |
CIRM Stem Cell Biology Training Program |
$5,827,817 |
| Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Research Training II |
Training in the Biology of Human Embryonic Stem Cells and Emerging Technologies II |
$2,886,221 |
| University of California, Santa Cruz |
Dr. David Haussler |
Research Training II |
UCSC CIRM Training Program in Systems Biology of Stem cells |
$4,397,002 |
| University of California, Irvine |
Dr. Peter John Donovan Dr. |
Research Training II |
UCI-CIRM Research Training Program II |
$6,067,550 |
| City of Hope, Beckman Research Institute |
Dr. Michael E. Barish Ph, D. |
Research Training II |
City of Hope Research Training Program in Stem Cell Biology |
$2,197,782 |
| Geron Corporation |
Dr. Jane Stephanie Lebkowski Dr. |
Targeted Clinical Development |
Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury |
$0 |
| City of Hope, Beckman Research Institute |
Dr. Jiing-Kuan Yee Ph.D. |
Basic Biology III |
Use of human iPS cells to study spinal muscular atrophy |
$1,268,868 |
| University of California, Los Angeles |
Dr. Yi Eve Sun |
Basic Biology III |
Studying neurotransmission of normal and diseased human ES cell-derived neurons in vivo |
$1,382,400 |
| University of California, San Diego |
Dr. Deborah H Spector Dr. |
Basic Biology III |
Viral-host interactions affecting neural differentiation of human progenitors |
$1,372,660 |
| Stanford University |
Dr. Aaron J Hsueh |
Basic Biology III |
Correlated time-lapse imaging and single cell molecular analysis of human embryo development |
$1,259,733 |
| University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
Basic Biology III |
Discovery of mechanisms that control epigenetic states in human reprogramming and pluripotent cells |
$1,364,598 |
| University of California, San Diego |
Dr. David A. Cheresh |
Basic Biology III |
Molecular basis of human ES cell neurovascular differentiation and co-patterning |
$1,359,996 |
| University of California, San Diego |
Dr. Anirvan Ghosh Dr. |
Basic Biology III |
Investigation of synaptic defects in autism using patient-derived induced pluripotent stem cells |
$843,597 |
| University of California, San Diego |
Dr. Kun Zhang |
Basic Biology III |
Functional characterization of mutational load in nuclear reprogramming and differentiation |
$1,295,318 |
| University of California, San Francisco |
Jason Harris Pomerantz |
Basic Biology III |
Phenotypic Analysis of Human ES Cell-Derived Muscle Stem Cells |
$1,381,296 |
| Scripps Research Institute |
Dr. Joel M Gottesfeld |
Basic Biology III |
Triplet Repeat Instability in Human iPSCs |
$1,705,494 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Basic Biology III |
Neural and general splicing factors control self-renewal, neural survival and differentiation |
$1,287,619 |
| Gladstone Institutes, J. David |
Dr. Deepak Srivastava |
Basic Biology III |
Mechanisms of Direct Cardiac Reprogramming |
$1,572,380 |
| Stanford University |
Sean M. Wu |
Basic Biology III |
Elucidating Molecular Basis of Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells |
$1,260,537 |
| University of California, Los Angeles |
Dr. Ali Nsair MD |
Basic Biology III |
Characterization and Engineering of the Cardiac Stem Cell Niche |
$1,127,741 |
| Stanford University |
Dr. Michael F Clarke |
Basic Biology III |
USP16 controls stem cell number: implications for Down Syndrome |
$1,263,826 |
| University of California, San Francisco |
John Murnane |
Basic Biology III |
Genomic instability during culturing of human embryonic stem cells |
$1,070,919 |
| University of California, San Diego |
Dr. Binhai Zheng Dr. |
Basic Biology III |
Generation and characterization of corticospinal neurons from human embryonic stem cells |
$1,355,063 |
| Stanford University |
Dr. Joanna Wysocka PhD |
Basic Biology III |
Enhancer-mediated gene regulation during early human embryonic development |
$1,420,618 |
| University of California, San Diego |
Dr. Farah Sheikh Dr. |
Basic Biology III |
Molecular Mechanisms Underlying Human Cardiac Cell Junction Maturation and Disease Using Human iPSC |
$1,341,955 |
| University of California, Los Angeles |
William Lowry |
Basic Biology III |
Molecular determinants of accurate differentiation from human pluripotent stem cells |
$677,115 |
| University of California, Los Angeles |
Dr. Shuo Lin Dr. |
Basic Biology III |
Etsrp/ER71 mediated stem cell differentiation into vascular lineage |
$1,378,781 |
| Parkinson’s Institute |
R. Jeremy Nichols |
Basic Biology III |
Understanding the role of LRRK2 in iPSC cell models of Parkinson’s Disease |
$1,482,822 |
| Scripps Research Institute |
Kristin Baldwin |
Basic Biology III |
Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing |
$1,705,500 |
| Stanford University |
Dr. Katja Weinacht |
Preclinical Stage Projects |
Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells |
$12,999,871 |
| EVADE Therapeutics |
Sonja Schrepfer |
Preclinical Stage Projects |
Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes |
$12,480,000 |
| University of Southern California |
Charles Murry |
Preclinical Stage Projects |
Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. |
$7,499,998 |
| University of California, Los Angeles |
Dr. Lili Yang |
Preclinical Stage Projects |
Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis |
$7,499,996 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
